The number of clinical trials in which AI designed or repurposed molecules, or targeted diseases, has more than doubled since ...

Deborah McElhone, Head of Sustainability (Pharma) from CPI, argues that process intensification is a game changer for the ...

The next FDA Commissioner could solve two big problems with one powerful policy: encourage independent testing of both ...

The grants have been the source of new treatments for cancer, heart disease, diabetes, strokes and H.I.V.; wonder drugs like ...

A reporter uncovers evidence that research fraud on a massive scale has hyped the potential benefit of expensive drugs aimed ...

Biotech stocks are revolutionizing healthcare with breakthrough innovations, leading the charge in precision therapies and ...

Investors are undervaluing promising drug candidates on the horizon for the two pharma giants, write Yale SOM’s Jeffrey ...

The Trump administration has targeted $4 billion in cuts to “indirect” costs for NIH research grants. Those funds, typically ...

It’s critical to understand what a digitally savvy HCP is in 2025 and what’s impeding pharma's communications with this ...

Access to data and to skills specific to AI are among the key challenges pharma companies face to unlock the technology’s ...

Trump could either weaken the negotiations in a way that benefits the pharmaceutical industry, or try to achieve even deeper savings to outdo his predecessor.

Drug industry calls out telehealth company Hims & Hers' Super Bowl ad touting its knock-off weight loss medications.